Breaking News

Pfizer Invests $35M in Anokion and Celiac Disease Candidate

Proceeds to fund Anokion's Phase 2 clinical program of KAN-101 in celiac disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer, through its Breakthrough Growth Initiative, has made a $35 million equity investment in Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance. In conjunction with the investment, Michael Vincent, M.D., Ph.D., senior vice president and chief scientific officer, Inflammation & Immunology, Pfizer, has joined the company’s scientific advisory board, and Allison Kean, M.D., executive director, Worldwide Business Deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters